|Bid||186.41 x 800|
|Ask||186.49 x 1300|
|Day's Range||185.11 - 187.49|
|52 Week Range||184.78 - 280.99|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||17.82|
|Earnings Date||Oct 27, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||258.59|
Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.
With drug pricing reform on the horizon, investors may want to analyze their allocation.
For nearly 18 months, investors have enjoyed a historic bounce-back rally in the stock market. The following trio of stocks are all down at least 33%, if not more, from their 52-week highs, but can be confidently bought hand over fist by investors. The first winning stock that's been beaten down of late is technology-driven real estate company Redfin (NASDAQ: RDFN).